These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23401252)

  • 1. Group testing regression model estimation when case identification is a goal.
    Zhang B; Bilder CR; Tebbs JM
    Biom J; 2013 Mar; 55(2):173-89. PubMed ID: 23401252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informative Dorfman screening.
    McMahan CS; Tebbs JM; Bilder CR
    Biometrics; 2012 Mar; 68(1):287-96. PubMed ID: 21762119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informative Retesting.
    Bilder CR; Tebbs JM; Chen P
    J Am Stat Assoc; 2010 Sep; 105(491):942-955. PubMed ID: 21113353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group testing regression models with fixed and random effects.
    Chen P; Tebbs JM; Bilder CR
    Biometrics; 2009 Dec; 65(4):1270-8. PubMed ID: 19210734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-dimensional informative array testing.
    McMahan CS; Tebbs JM; Bilder CR
    Biometrics; 2012 Sep; 68(3):793-804. PubMed ID: 22212007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-stage hierarchical group testing for multiple infections with application to the infertility prevention project.
    Tebbs JM; McMahan CS; Bilder CR
    Biometrics; 2013 Dec; 69(4):1064-73. PubMed ID: 24117173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in the screening for Chlamydia trachomatis: a review.
    Kohl KS; Markowitz LE; Koumans EH
    Obstet Gynecol Clin North Am; 2003 Dec; 30(4):637-58. PubMed ID: 14719842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global goodness-of-fit tests for group testing regression models.
    Chen P; Tebbs JM; Bilder CR
    Stat Med; 2009 Oct; 28(23):2912-28. PubMed ID: 19610130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression analysis for multiple-disease group testing data.
    Zhang B; Bilder CR; Tebbs JM
    Stat Med; 2013 Dec; 32(28):4954-66. PubMed ID: 23703944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled-testing procedures for screening high volume clinical specimens in heterogeneous populations.
    Bilder CR; Tebbs JM
    Stat Med; 2012 Nov; 31(27):3261-8. PubMed ID: 22415972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression models for disease prevalence with diagnostic tests on pools of serum samples.
    Vansteelandt S; Goetghebeur E; Verstraeten T
    Biometrics; 2000 Dec; 56(4):1126-33. PubMed ID: 11129470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group testing regression models with dilution submodels.
    Warasi MS; McMahan CS; Tebbs JM; Bilder CR
    Stat Med; 2017 Dec; 36(30):4860-4872. PubMed ID: 28856774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression analysis and variable selection for two-stage multiple-infection group testing data.
    Lin J; Wang D; Zheng Q
    Stat Med; 2019 Oct; 38(23):4519-4533. PubMed ID: 31297869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An asymptotic approximation to the N-mixture model for the estimation of disease prevalence.
    Brintz B; Fuentes C; Madsen L
    Biometrics; 2018 Dec; 74(4):1512-1518. PubMed ID: 29870071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalized additive regression for group testing data.
    Liu Y; McMahan CS; Tebbs JM; Gallagher CM; Bilder CR
    Biostatistics; 2021 Oct; 22(4):873-889. PubMed ID: 32061081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A probit latent class model with general correlation structures for evaluating accuracy of diagnostic tests.
    Xu H; Craig BA
    Biometrics; 2009 Dec; 65(4):1145-55. PubMed ID: 19210729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlamydia positivity versus prevalence. What's the difference?
    Dicker LW; Mosure DJ; Levine WC
    Sex Transm Dis; 1998 May; 25(5):251-3. PubMed ID: 9587176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian sample size determination for prevalence and diagnostic test studies in the absence of a gold standard test.
    Dendukuri N; Rahme E; Bélisle P; Joseph L
    Biometrics; 2004 Jun; 60(2):388-97. PubMed ID: 15180664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using chlamydia positivity to estimate prevalence: evidence from the Chlamydia Screening Pilot in England.
    LaMontagne DS; Fenton KA; Pimenta JM; Catchpole M; Rogers PA; Randall S; Hewitt WG; Mallinson H; Underhill GS; McLean L; Gleave T; Harindra V; Ghosh AK; Tobin JM
    Int J STD AIDS; 2005 Apr; 16(4):323-7. PubMed ID: 15899088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retesting and repeat positivity following diagnosis of Chlamydia trachomatis and Neisseria gonorrhoea in New Zealand: a retrospective cohort study.
    Rose SB; Garrett SM; Stanley J; Pullon SRH
    BMC Infect Dis; 2017 Jul; 17(1):526. PubMed ID: 28754106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.